top-home.jpg

Starpharma completes A$18 million placement - SPP to follow

Annual Report 2014
Annual Report 2014

Annual Report and full year financial results

The Business on ABC TV: Interview with Starpharma CEO Jackie Fairley

VivaGel® condom receives TGA device certification - Launch preparations to follow

FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial

Sexual Health Drug Delivery Agrochemicals Wider Applications
         
 

Starpharma Holdings Limited is a world leader in the development of dendrimer products for pharmaceutical, life-science and other applications.

Starpharma’s lead products based on VivaGel® (SPL7013, astodrimer sodium) are for the management of bacterial vaginosis (BV), and for prevention of transmission of sexually transmitted infections (STIs), including HIV and genital herpes.  The VivaGel® condom has been licensed to Ansell and Okamoto.  A VivaGel® condom has obtained conformity assessment certification from the Australian Therapeutic Goods Administration (TGA).  Regulatory certification (marketing approval) has also been granted for marketing by Okamoto of the VivaGel® condom in Japan.received marketing approval in Japan.

 

 

In the wider pharmaceutical and life science fields, Starpharma has specific programs in dendrimer drug delivery, including drug targeting, drug solubilisation, diagnostics and pharmaceutical excipients.

More broadly, Starpharma is exploring dendrimer opportunities in agrochemicals, cosmetics and materials science with applications as diverse as paints, coatings, adhesives, and water remediation.

 
         

invester-center.jpg

Code Last $+/-
SPL 0.715 0.055

Data provided by asx.com.au. Prices are delayed by at least 20 minutes.

© Starpharma Holdings Limited 2014